Detalhe da pesquisa
1.
Bimekizumab in patients with psoriatic arthritis, naive to biologic treatment: a randomised, double-blind, placebo-controlled, phase 3 trial (BE OPTIMAL).
Lancet
; 401(10370): 25-37, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36493791
2.
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE).
Lancet
; 401(10370): 38-48, 2023 01 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36495881
3.
Bimekizumab versus Adalimumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 130-141, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891379
4.
Bimekizumab versus Secukinumab in Plaque Psoriasis.
N Engl J Med
; 385(2): 142-152, 2021 07 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33891380
5.
The association of age at psoriasis onset and HLA-C*06:02 with biologic survival in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol
; 190(5): 689-700, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38051972
6.
Bimekizumab safety in patients with moderate-to-severe plaque psoriasis: pooled data from up to 3â years of treatment in randomized phase III trials.
Br J Dermatol
; 190(4): 477-485, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37950894
7.
Deucravacitinib in plaque psoriasis: 2-year safety and efficacy results from the phase III POETYK trials.
Br J Dermatol
; 190(5): 668-679, 2024 Apr 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-38226713
8.
Discontinuation of anti-tumour necrosis factor alpha treatment owing to blood test abnormalities, and cost-effectiveness of alternate blood monitoring strategies.
Br J Dermatol
; 190(4): 559-564, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37931161
9.
Orismilast in moderate-to-severe psoriasis: Efficacy and safety from a 16-week, randomized, double-blinded, placebo-controlled, dose-finding, and phase 2b trial (IASOS).
J Am Acad Dermatol
; 90(3): 494-503, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37951245
10.
Deucravacitinib in moderate-to-severe plaque psoriasis: Pooled safety and tolerability over 52 weeks from two phase 3 trials (POETYK PSO-1 and PSO-2).
J Eur Acad Dermatol Venereol
; 2024 Mar 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38451052
11.
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics.
J Allergy Clin Immunol
; 152(5): 1237-1246, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37536512
12.
Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease.
Am J Hum Genet
; 107(3): 539-543, 2020 09 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32758448
13.
Bimekizumab treatment in biologic DMARD-naïve patients with active psoriatic arthritis: 52-week efficacy and safety results from the phase III, randomised, placebo-controlled, active reference BE OPTIMAL study.
Ann Rheum Dis
; 82(11): 1404-1414, 2023 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-37696588
14.
Association between psoriatic disease and lifestyle factors and comorbidities: cross-sectional analysis and Mendelian randomization.
Rheumatology (Oxford)
; 62(3): 1272-1285, 2023 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35861400
15.
The risk of venous thromboembolism in atopic dermatitis: a matched cohort analysis in UK primary care.
Br J Dermatol
; 189(4): 427-436, 2023 09 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-37418627
16.
Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR).
Br J Dermatol
; 189(1): 62-70, 2023 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-37016153
17.
Effectiveness and survival of methotrexate versus adalimumab in patients with moderate-to-severe psoriasis: a cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Br J Dermatol
; 189(3): 271-278, 2023 08 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37226927
18.
Imsidolimab, an anti-interleukin-36 receptor monoclonal antibody, for the treatment of generalized pustular psoriasis: results from the phase II GALLOP trial.
Br J Dermatol
; 189(2): 161-169, 2023 07 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-37120722
19.
Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials.
Br J Dermatol
; 188(2): 198-207, 2023 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36763857
20.
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Br J Dermatol
; 188(3): 330-340, 2023 02 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36751950